• Something wrong with this record ?

Apolipoprotein A5 in health and disease

J. A. Hubáček, V. Adámková, M. Vrablík, M. Kadlecová, J. Zicha, J. Kuneš, J. Piťha, P. Suchánek, R. Poledne

. 2009 ; 58 (Suppl. 2) : S101 - S109.
. 2009 ; 58 (Suppl. 2) : S101 - S109.

Language English Country Czech Republic

Document type Review

Grant support
NR8895 MZ0 CEP Register
NR9393 MZ0 CEP Register

High plasma levels of triglycerides (TG) are an independent risk factor in the development of cardiovascular disease, with about 50 % of the final levels being determined genetically. Apolipoprotein A5 (APOA5) is the last discovered member of the apolipoprotein APOA1/C3/A4 gene cluster, found by comparative sequencing analysis. The importance of APOA5 gene for determination of plasma triglyceride levels has been suggested after development of transgenic and knock-out mice (transgenic mice displayed significantly reduced TG, whereas knock-out mice had high TG). In Czech population, alleles C-1131 and Trp19 are associated with elevated levels of plasma TG and higher risk of myocardial infarction development. These alleles also play some role in nutrigenetics and actigenetics of lifestyle interventions leading to the plasma cholesterol changes as well as in the pharmacogenetics of statin treatment. On the contrary, APOA5 mutations detected in Czech population did not show strict effect on plasma TG levels. Val153 --> Met variant exhibit the sex-specific effect of HDL-cholesterol levels. The suggested roles of APOA5 variants in determination of the plasma remnant particles, plasma concentrations of C-reactive protein or some anthropometrical parameters were excluded.

References provided by Crossref.org

Bibliography, etc.

Lit.: 42

000      
00000naa 2200000 a 4500
001      
bmc10013431
003      
CZ-PrNML
005      
20151006141217.0
008      
100604s2009 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931911 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Hubáček, Jaroslav, $d 1966- $7 nlk20050169367
245    10
$a Apolipoprotein A5 in health and disease / $c J. A. Hubáček, V. Adámková, M. Vrablík, M. Kadlecová, J. Zicha, J. Kuneš, J. Piťha, P. Suchánek, R. Poledne
314    __
$a Center for Cardiovascular Research, Prague jahb@ikem.cz
504    __
$a Lit.: 42
520    9_
$a High plasma levels of triglycerides (TG) are an independent risk factor in the development of cardiovascular disease, with about 50 % of the final levels being determined genetically. Apolipoprotein A5 (APOA5) is the last discovered member of the apolipoprotein APOA1/C3/A4 gene cluster, found by comparative sequencing analysis. The importance of APOA5 gene for determination of plasma triglyceride levels has been suggested after development of transgenic and knock-out mice (transgenic mice displayed significantly reduced TG, whereas knock-out mice had high TG). In Czech population, alleles C-1131 and Trp19 are associated with elevated levels of plasma TG and higher risk of myocardial infarction development. These alleles also play some role in nutrigenetics and actigenetics of lifestyle interventions leading to the plasma cholesterol changes as well as in the pharmacogenetics of statin treatment. On the contrary, APOA5 mutations detected in Czech population did not show strict effect on plasma TG levels. Val153 --> Met variant exhibit the sex-specific effect of HDL-cholesterol levels. The suggested roles of APOA5 variants in determination of the plasma remnant particles, plasma concentrations of C-reactive protein or some anthropometrical parameters were excluded.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a apolipoproteiny $x genetika $7 D001053
650    _2
$a apolipoproteiny A $x genetika $x krev $7 D001054
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a hypercholesterolemie $x genetika $x krev $7 D006937
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a infarkt myokardu $x genetika $x krev $x prevence a kontrola $7 D009203
650    _2
$a fenotyp $7 D010641
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a triglyceridy $x krev $7 D014280
655    _2
$a přehledy $7 D016454
700    1_
$a Adámková, Věra, $d 1954- $7 jx20050329003
700    1_
$a Vrablík, Michal, $d 1973- $7 xx0061419
700    1_
$a Kadlecová, Michaela, $d 1976- $7 xx0053597
700    1_
$a Zicha, Josef, $d 1950- $7 jk01152609
700    1_
$a Kuneš, Jaroslav, $d 1948- $7 nlk19990073450
700    1_
$a Piťha, Jan, $d 1964- $7 mzk2003187379
700    1_
$a Suchánek, Pavel, $d 1972- $7 xx0016857
700    1_
$a Poledne, Rudolf, $d 1940- $7 nlk20040147088
773    0_
$w MED00003824 $t Physiological research $g Roč. 58,Suppl. 2 (2009), s. S101 - S109 $x 0862-8408
773    0_
$t Center for cardiovascular research $g Roč. 58,Suppl. 2 (2009), s. S101 - S109 $w MED00173857
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/58%20Suppl%202/58_S101.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 8 $z 0
990    __
$a 20100603155515 $b ABA008
991    __
$a 20151006141401 $b ABA008
999    __
$a ok $b bmc $g 749294 $s 612935
BAS    __
$a 3
BMC    __
$a 2009 $b 58 $c Suppl. 2 $d S101 - S109 $m Physiological research $x MED00003824
BMC    __
$a 2009 $b 58 $c Suppl. 2 $d S101 - S109 $m Center for cardiovascular research $x MED00173857
GRA    __
$a NR8895 $p MZ0
GRA    __
$a NR9393 $p MZ0
LZP    __
$a 2010-15/mkme

Find record

Citation metrics

Loading data ...